Recent progress in the pathogenesis and management of essential thrombocythemia

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In the last decade, the diagnosis of essential thrombocythemia (ET) has been refined by appreciation of the occurrence of karyotypically occult but molecularly evident chronic myelogenous leukemia and morphologically subtle myelodysplastic syndrome (MDS) and cellular-phase agnogenic myeloid metaplasia (AMM). Although ET continues to be defined by the presence of nonreactive thrombocythemia that is not accounted for by another chronic myeloid disorder, recent studies of clonality and other laboratory parameters have suggested clinically relevant biologic heterogeneity among affected patients. Furthermore, randomized, prospective, and controlled retrospective data have provided additional clinical information that has resulted in the development of risk categories and risk-adjusted treatment recommendations.

Original languageEnglish (US)
Pages (from-to)369-377
Number of pages9
JournalLeukemia Research
Volume25
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Essential Thrombocythemia
Thrombocytosis
Primary Myelofibrosis
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics

Keywords

  • Chronic myeloproliferative disease
  • Cytoreductive therapy
  • Essential thrombocythemia
  • Hematopoiesis
  • Thrombopoietin
  • Thrombosis

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Recent progress in the pathogenesis and management of essential thrombocythemia. / Tefferi, Ayalew.

In: Leukemia Research, Vol. 25, No. 5, 2001, p. 369-377.

Research output: Contribution to journalArticle

@article{81aa261f58c5456e90189de696923776,
title = "Recent progress in the pathogenesis and management of essential thrombocythemia",
abstract = "In the last decade, the diagnosis of essential thrombocythemia (ET) has been refined by appreciation of the occurrence of karyotypically occult but molecularly evident chronic myelogenous leukemia and morphologically subtle myelodysplastic syndrome (MDS) and cellular-phase agnogenic myeloid metaplasia (AMM). Although ET continues to be defined by the presence of nonreactive thrombocythemia that is not accounted for by another chronic myeloid disorder, recent studies of clonality and other laboratory parameters have suggested clinically relevant biologic heterogeneity among affected patients. Furthermore, randomized, prospective, and controlled retrospective data have provided additional clinical information that has resulted in the development of risk categories and risk-adjusted treatment recommendations.",
keywords = "Chronic myeloproliferative disease, Cytoreductive therapy, Essential thrombocythemia, Hematopoiesis, Thrombopoietin, Thrombosis",
author = "Ayalew Tefferi",
year = "2001",
doi = "10.1016/S0145-2126(00)00131-4",
language = "English (US)",
volume = "25",
pages = "369--377",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Recent progress in the pathogenesis and management of essential thrombocythemia

AU - Tefferi, Ayalew

PY - 2001

Y1 - 2001

N2 - In the last decade, the diagnosis of essential thrombocythemia (ET) has been refined by appreciation of the occurrence of karyotypically occult but molecularly evident chronic myelogenous leukemia and morphologically subtle myelodysplastic syndrome (MDS) and cellular-phase agnogenic myeloid metaplasia (AMM). Although ET continues to be defined by the presence of nonreactive thrombocythemia that is not accounted for by another chronic myeloid disorder, recent studies of clonality and other laboratory parameters have suggested clinically relevant biologic heterogeneity among affected patients. Furthermore, randomized, prospective, and controlled retrospective data have provided additional clinical information that has resulted in the development of risk categories and risk-adjusted treatment recommendations.

AB - In the last decade, the diagnosis of essential thrombocythemia (ET) has been refined by appreciation of the occurrence of karyotypically occult but molecularly evident chronic myelogenous leukemia and morphologically subtle myelodysplastic syndrome (MDS) and cellular-phase agnogenic myeloid metaplasia (AMM). Although ET continues to be defined by the presence of nonreactive thrombocythemia that is not accounted for by another chronic myeloid disorder, recent studies of clonality and other laboratory parameters have suggested clinically relevant biologic heterogeneity among affected patients. Furthermore, randomized, prospective, and controlled retrospective data have provided additional clinical information that has resulted in the development of risk categories and risk-adjusted treatment recommendations.

KW - Chronic myeloproliferative disease

KW - Cytoreductive therapy

KW - Essential thrombocythemia

KW - Hematopoiesis

KW - Thrombopoietin

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0035071899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035071899&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(00)00131-4

DO - 10.1016/S0145-2126(00)00131-4

M3 - Article

VL - 25

SP - 369

EP - 377

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 5

ER -